Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.

Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A.

Int J Mol Sci. 2019 Oct 2;20(19). pii: E4886. doi: 10.3390/ijms20194886. Review.

2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.

Evangelista L, Basso U, Maruzzo M, Novara G.

Eur Urol Focus. 2018 Aug 14. pii: S2405-4569(18)30223-2. doi: 10.1016/j.euf.2018.08.004. [Epub ahead of print] Review.

PMID:
30120074
4.

A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I.

Mol Imaging Biol. 2019 Oct;21(5):799-807. doi: 10.1007/s11307-018-01307-0.

PMID:
30617728
5.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

6.

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N.

Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review.

PMID:
27363387
7.

Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.

Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.

J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378. doi: 10.1111/1754-9485.12590. Epub 2017 Jan 24. Review.

PMID:
28116853
8.

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG.

Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095-8. doi: 10.1016/j.eururo.2019.01.049. [Epub ahead of print] Review.

PMID:
30773328
9.

Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.

Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, Turkmen C.

Clin Nucl Med. 2019 Sep;44(9):702-706. doi: 10.1097/RLU.0000000000002701.

PMID:
31348076
10.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.

Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.

PMID:
26850970
11.
12.

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME.

Ann Nucl Med. 2015 Dec;29(10):877-82. doi: 10.1007/s12149-015-1017-z. Epub 2015 Aug 19.

13.

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.

Corfield J, Perera M, Bolton D, Lawrentschuk N.

World J Urol. 2018 Apr;36(4):519-527. doi: 10.1007/s00345-018-2182-1. Epub 2018 Jan 17. Review.

PMID:
29344682
14.

68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.

Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E.

J Nucl Med. 2018 Jul 12. pii: jnumed.118.214833. doi: 10.2967/jnumed.118.214833. [Epub ahead of print]

15.

Comparative study between 68 Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.

Wong HS, Leung J, Bartholomeusz D, Sutherland P, Le H, Nottage M, Iankov I, Chang JH.

J Med Imaging Radiat Oncol. 2018 Dec;62(6):816-822. doi: 10.1111/1754-9485.12791. Epub 2018 Aug 28.

PMID:
30152050
16.
17.

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.

J Urol. 2016 May;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.

PMID:
26682756
18.

Potential of radiolabelled PSMA PET/CT or PET/MRI diagnostic procedures in gliomas/glioblastomas.

Bertagna F, Albano D, Cerudelli E, Gazzilli M, Giubbini R, Treglia G.

Curr Radiopharm. 2019 Oct 16. doi: 10.2174/1874471012666191017093721. [Epub ahead of print]

PMID:
31625482
19.

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Arsenault F, Beauregard JM, Pouliot F.

Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357. Review.

PMID:
29939893
20.

Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.

Afaq A, Bomanji J.

Br Med Bull. 2018 Dec 1;128(1):37-48. doi: 10.1093/bmb/ldy032. Review.

PMID:
30272121

Supplemental Content

Support Center